Investors who lost money on Altimmune, Inc.(ALT) should contact Levi & Korsinsky about pending Class Actio... ACCESSWIRE
Market data is delayed by at least 15 minutes.
    Latest Story Top Stories on ALT
    Altimmune Statement on the Passing of Dr. Stephen Harrison
    5:25p ET April 25 '24 GlobeNewswire
    Altimmune Statement on the Passing of Dr. Stephen HarrisonGlobeNewswireApril 25, 2024

    GAITHERSBURG, Md., April 25, 2024 (GLOBE NEWSWIRE) -- The Altimmune team would like to express our sorrow and extend our heartfelt condolences to Dr. Stephen Harrison's family following his tragic and unexpected passing.

    Dr. Harrison's countless contributions to advancing needed treatments for metabolic liver disease will leave a profound and lasting legacy throughout our field, with his patients and the people engaged in understanding and treating liver disease. His brilliance and vision were only rivaled by his eloquence, charisma and steadfast commitment to improving the lives of people with liver disease. He was a tireless advocate for patients and a deeply respected advisor, investigator and friend to Altimmune.

    We will miss him greatly as we adjust to this tremendous loss for the community. We honor his memory and are grateful for having known and worked with him.

    Contact:Rich EisenstadtChief Financial OfficerPhone: 240-654-1450reisenstadt@altimmune.com

    COMTEX_451423831/2010/2024-04-25T17:25:22

    GAITHERSBURG, Md., April 25, 2024 (GLOBE NEWSWIRE) -- The Altimmune team would like to express our sorrow and extend our heartfelt condolences to Dr. Stephen Harrison's family following his tragic and unexpected passing.

    Dr. Harrison's countless contributions to advancing needed treatments for metabolic liver disease will leave a profound and lasting legacy throughout our field, with his patients and the people engaged in understanding and treating liver disease. His brilliance and vision were only rivaled by his eloquence, charisma and steadfast commitment to improving the lives of people with liver disease. He was a tireless advocate for patients and a deeply respected advisor, investigator and friend to Altimmune.

    We will miss him greatly as we adjust to this tremendous loss for the community. We honor his memory and are grateful for having known and worked with him.

    Contact:Rich EisenstadtChief Financial OfficerPhone: 240-654-1450reisenstadt@altimmune.com

    COMTEX_451423831/2010/2024-04-25T17:25:22

    ROSEN, LEADING TRIAL ATTORNEYS, Encourages Altimmune, Inc. Investors ...
    11:08a ET May 18 '24 Newsfile Corp
    SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losse...
    9:15a ET May 18 '24 Newsfile Corp
    SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behal...
    7:09a ET May 18 '24 Newsfile Corp
    ROSEN, NATIONAL TRIAL LAWYERS, Encourages Altimmune, Inc. Investors t...
    6:11p ET May 17 '24 GlobeNewswire
    Levi & Korsinsky Notifies Altimmune, Inc. Investors of a Class Action...
    1:17p ET May 17 '24 ACCESSWIRE
    Levi & Korsinsky Notifies Altimmune, Inc. Investors of a Class Action...
    1:17p ET May 17 '24 ACCESSWIRE
    Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Act...
    1:11p ET May 17 '24 GlobeNewswire
    July 5, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action ...
    1:01p ET May 17 '24 ACCESSWIRE
    DEADLINE ALERT for ALT, AXTI, HRBR, and LI: The Law Offices of Frank ...
    12:07p ET May 17 '24 GlobeNewswire
    July 5, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action ...
    12:02p ET May 17 '24 ACCESSWIRE

    Market data provided by News provided by